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Abstract 
Background Carbamazepine (CBZ) therapy is associated with hypersensitivity reactions, which can be multisystemic 
and sometimes fatal. The pathogenesis of these reactions is incompletely understood but heterologous immunity 
generated to viral antigens has been proposed as a potential mechanism. Our aim was to investigate changes in gene 
expression proﬁ les of peripheral blood mononuclear cells (PBMCs) from patients with CBZ hypersensitivity 
to characterise the pathways involved in immune activation.
Methods PBMCs were isolated from ﬁ ve individuals with a history of hypersensitivity to CBZ. The PBMCs were 
incubated for 24 h with CBZ, carbamazepine 10,11-epoxide (CBZE), cell culture medium, or tetanus toxoid. Expression 
proﬁ les for mRNA and microRNA were generated with microarrays (Aﬀ ymetrix, Santa Clara, CA, USA). Diﬀ erential 
gene expression was undertaken by limma analysis in the R statistical software. Ingenuity pathway analysis (IPA) was 
used to deﬁ ne the molecular mechanisms in development of CBZ hypersensitivity.
Findings Incubation of PBMCs with CBZ, CBZE, and tetanus toxoid led to signiﬁ cant diﬀ erential expression (log2-fold 
change >1 or <–1, p<0·05) of multiple mRNA (n=204) and microRNA (n=148) transcripts with little overlap between the 
diﬀ erent incubation conditions. The top diﬀ erentially expressed genes for CBZ-treated and CBZE-treated cells identiﬁ ed 
in IPA analysis were COX8A, IFI35, IFIT3, PARP9, PARP12, PTGES, RSAD2, USP18, USP41, miR433, miR455, 
miR3194, miR4723, and miR345. These genes were highly interconnected in functional networks and deﬁ ned ﬁ ve top 
functional categories—namely, viral infection, psoriasis, inﬂ ammation of body region or organ, and antiviral response.
Interpretation Incubation of PBMCs from CBZ hypersensitive individuals with CBZ or CBZE led to treatment-
speciﬁ c changes in gene expression associated with activation of antiviral and inﬂ ammatory pathways. These 
CBZ-speciﬁ c and CBZE-speciﬁ c mRNA and microRNA changes could potentially act as novel diagnostic biomarkers 
and treatment targets for CBZ hypersensitivity reactions, but further validation and conﬁ rmation of speciﬁ city in 
larger numbers of patients are needed.
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